Imgatuzumab
PO-001
Phase 2 small_molecule terminated
Quick answer
Imgatuzumab for Cutaneous Squamous Cell Carcinoma is a Phase 2 program (small_molecule) at Centessa Pharmaceuticals plc with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Centessa Pharmaceuticals plc
- Indication
- Cutaneous Squamous Cell Carcinoma
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- terminated